Histone Deacetylase Inhibitors in Castration-resistant Prostate Cancer: Molecular Mechanism of Action and Recent Clinical Trials

Overview

Journal Ther Adv Urol

Publisher Sage Publications

Date 2015 Dec 2

PMID 26622323

Citations 28

Authors

Dharam Kaushik

Vishal Vashistha

Sudhir Isharwal

Soud A Sediqe

Ming-Fong Lin

Affiliations

Soon will be listed here.

Abstract

Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic prostate cancer. Unfortunately, nearly majority patients with prostate cancer transition to the refractory state of castration-resistant prostate cancer (CRPC). Newer therapeutic agents are needed for treating these CRPC patients that are unresponsive to androgen deprivation and/or chemotherapy. The histone deacetylase (HDAC) family of enzymes limits the expression of genomic regions by improving binding between histones and the DNA backbone. Modulating the role of HDAC enzymes can alter the cell's regulation of proto-oncogenes and tumor suppressor genes, thereby regulating potential neoplastic proliferation. As a result, histone deacetylase inhibitors (HDACi) are now being evaluated for CRPC or chemotherapy-resistant prostate cancer due to their effects on the expression of the androgen receptor gene. In this paper, we review the molecular mechanism and functional target molecules of different HDACi as applicable to CRPC as well as describe recent and current clinical trials involving HDACi in prostate cancer. To date, four HDAC classes comprising 18 isoenzymes have been identified. Recent clinical trials of vorinostat, romidepsin, and panobinostat have provided cautious optimism towards improved outcomes using these novel therapeutic agents for CPRC patients. Nevertheless, no phase III trial has been conducted to cement one of these drugs as an adjunct to androgen-deprivation therapy. Consequently, further investigation is necessary to delineate the benefits and drawbacks of these medications.

Citing Articles

Natural Compounds and Histone Deacetylase Inhibitors: A Combined Approach Against mCRPC Cells.

Alimudin J, Betts Z, Deveci Ozkan A Biomedicines. 2025; 13(2).

PMID: 40002709 PMC: 11853668. DOI: 10.3390/biomedicines13020296.

Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review.

Maekawa S, Takata R, Obara W Cancers (Basel). 2024; 16(3).

PMID: 38339274 PMC: 10854717. DOI: 10.3390/cancers16030523.

Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer.

Pramanik S, Halder A, Mukherjee U, Kumar D, Dey Y, R M Front Chem. 2022; 10:948217.

PMID: 36034650 PMC: 9411967. DOI: 10.3389/fchem.2022.948217.

Transcriptomic analysis reveals the key role of histone deacetylation via mediating different phytohormone signalings in fiber initiation of cotton.

Wei Z, Li Y, Ali F, Wang Y, Liu J, Yang Z Cell Biosci. 2022; 12(1):107.

PMID: 35831870 PMC: 9277824. DOI: 10.1186/s13578-022-00840-4.

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer.

Biersack B, Nitzsche B, Hopfner M Cancer Drug Resist. 2022; 5(1):64-79.

PMID: 35582529 PMC: 8992583. DOI: 10.20517/cdr.2021.105.

References

Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K . Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008; 98(3):604-10. PMC: 2243142. DOI: 10.1038/sj.bjc.6604199. View

Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

Yuan Z, Guan Y, Chatterjee D, Chin Y . Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005; 307(5707):269-73. DOI: 10.1126/science.1105166. View

Solit D, Scher H, Rosen N . Hsp90 as a therapeutic target in prostate cancer. Semin Oncol. 2003; 30(5):709-16. DOI: 10.1016/s0093-7754(03)00346-4. View

Perry A, Watson R, Lawler M, Hollywood D . The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol. 2010; 7(12):668-80. DOI: 10.1038/nrurol.2010.185. View

Bode A, Dong Z . Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 2004; 4(10):793-805. DOI: 10.1038/nrc1455. View

Chen C, Wang Y, Yang H, Huang P, Kulp S, Yang C . Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res. 2007; 67(11):5318-27. DOI: 10.1158/0008-5472.CAN-06-3996. View

Jayaraman R, Pilla Reddy V, Pasha M, Wang H, Sangthongpitag K, Yeo P . Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab Dispos. 2011; 39(12):2219-32. DOI: 10.1124/dmd.111.041558. View

Dillard P, Lin M, Khan S . Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol. 2008; 295(1-2):115-20. PMC: 2802176. DOI: 10.1016/j.mce.2008.08.013. View

10.

Fang Y, Fliss A, Robins D, Caplan A . Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem. 1996; 271(45):28697-702. DOI: 10.1074/jbc.271.45.28697. View

11.

Molife L, Attard G, Fong P, Karavasilis V, Reid A, Patterson S . Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol. 2009; 21(1):109-13. DOI: 10.1093/annonc/mdp270. View

12.

Bradley D, Rathkopf D, Dunn R, Stadler W, Liu G, Smith D . Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and.... Cancer. 2009; 115(23):5541-9. PMC: 2917101. DOI: 10.1002/cncr.24597. View

13.

Appella E, Anderson C . Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem. 2001; 268(10):2764-72. DOI: 10.1046/j.1432-1327.2001.02225.x. View

14.

Gu W, Shi X, Roeder R . Synergistic activation of transcription by CBP and p53. Nature. 1997; 387(6635):819-23. DOI: 10.1038/42972. View

15.

Roy S, Tenniswood M . Site-specific acetylation of p53 directs selective transcription complex assembly. J Biol Chem. 2006; 282(7):4765-4771. DOI: 10.1074/jbc.M609588200. View

16.

Neckers L, Ivy S . Heat shock protein 90. Curr Opin Oncol. 2003; 15(6):419-24. DOI: 10.1097/00001622-200311000-00003. View

17.

Feldman B, Feldman D . The development of androgen-independent prostate cancer. Nat Rev Cancer. 2002; 1(1):34-45. DOI: 10.1038/35094009. View

18.

Novotny-Diermayr V, Sangthongpitag K, Hu C, Wu X, Sausgruber N, Yeo P . SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther. 2010; 9(3):642-52. DOI: 10.1158/1535-7163.MCT-09-0689. View

19.

Chen L, Meng S, Wang H, Bali P, Bai W, Li B . Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005; 4(9):1311-9. DOI: 10.1158/1535-7163.MCT-04-0287. View

20.

Yu X, Guo Z, Marcu M, Neckers L, Nguyen D, Chen G . Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst. 2002; 94(7):504-13. DOI: 10.1093/jnci/94.7.504. View